A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis : A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ClinicalTrials.gov - (2024) vom: 15. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: April 16, 2019, Last downloaded: ClinicalTrials.gov processed this data on March 20, 2024, Last updated: March 20, 2024 |
|---|
| Study ID: |
NCT03915964 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG000085448 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG000085448 | ||
| 003 | DE-627 | ||
| 005 | 20240320010340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG000085448 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT03915964 | ||
| 035 | |a (UBBS_Klinische_Studien)17172 | ||
| 035 | |a (UBBS_Klinische_Studien)I4V-MC-JAJA | ||
| 035 | |a (UBBS_Klinische_Studien)2018-003351-37 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis |b A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: April 16, 2019, Last downloaded: ClinicalTrials.gov processed this data on March 20, 2024, Last updated: March 20, 2024 | ||
| 520 | |a This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis. | ||
| 650 | 2 | |a Arthritis | |
| 650 | 2 | |a Arthritis, Rheumatoid | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Active, not recruiting | |
| 650 | 4 | |a Phase: Phase 4 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 15. März |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:03 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT03915964 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 03 | ||